Todd Watanabe - 13 Feb 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Signature
/s/ Scott Burrows, Attorney-in-Fact for Todd Franklin Watanabe
Issuer symbol
ARQT
Transactions as of
13 Feb 2023
Transactions value $
-$17,012
Form type
4
Filing time
15 Feb 2023, 18:09:01 UTC
Previous filing
03 Feb 2023
Next filing
02 Mar 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Sale -$7.5K -441 -0.12% $17.00 377K 13 Feb 2023 Direct F1
transaction ARQT Common Stock Sale -$714 -42 -0.01% $17.01 377K 13 Feb 2023 Direct F1
transaction ARQT Common Stock Sale -$7.1K -417 -0.11% $17.02 377K 14 Feb 2023 Direct F1
transaction ARQT Common Stock Sale -$1.7K -100 -0.03% $17.03 377K 14 Feb 2023 Direct F1
holding ARQT Common Stock 17.9K 13 Feb 2023 By Trust F2
holding ARQT Common Stock 17.9K 13 Feb 2023 By Trust F3
holding ARQT Common Stock 125K 13 Feb 2023 By Trust F4
holding ARQT Common Stock 57.4K 13 Feb 2023 By LLC F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F3 The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F4 The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5 The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Remarks:

Reporting Person's title: Chief Executive Officer and President